Inhibikase Therapeutics logo
Inhibikase Therapeutics IKT
$ 3.2 0.0%

Quarterly report 2024-Q3
added 11-14-2024

report update icon

Inhibikase Therapeutics Cash Flow 2011-2024 | IKT

Annual Cash Flow Inhibikase Therapeutics

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

-18.1 M -17.4 M -14.3 M -1.13 M - - - - - - - - -

Depreciation & Amortization

177 K 6.72 K - - - - - - - - - - -

Accounts Payables

647 K 1.15 M 1.09 M - - - - - - - - - -

Accounts Receivables

- 39.9 K 110 K - - - - - - - - - -

Total Inventories

- - - - - - - - - - - - -

All numbers in USD currency

Quarterly Cash Flow Inhibikase Therapeutics

2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

- - -3.87 M - - - -5.97 M - -13.8 M -8.29 M -3.93 M - -10.2 M -8.18 M -3.93 M - -183 K -258 K -255 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Depreciation & Amortization

6.57 K 6.57 K 6.57 K - 6.57 K 159 K 5.04 K - 1.68 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Accounts Payables

2.53 M 1.34 M 1.29 M 647 K 735 K 754 K 959 K 1.15 M 781 K 860 K 806 K 1.09 M 554 K 897 K 715 K 1.72 M 1.72 M 1.72 M 1.72 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Accounts Receivables

- - - - - 79.6 K 64.5 K 39.9 K 13.8 K 6.55 K 48 K 110 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Inventories

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency